Abstract: Objective The aim of this study was to investigate the clinical efficacy of ursodeoxycholic acid （UDCA） in treatment of patients with intrahepatic cholestasis of pregnancy （ICP）. Methods 70 patients with ICP were recruited in our hospital between March 2015 and April 2018,and were randomly divided into observation and control group with 35 cases in each. The patients in control group were given conventional treatment,and those in the observation were given UDCA treatment for four weeks. Serum lithocholic acid （LCA）,UDCA,chenodeoxycholic acid （CDCA）,cholic acid （CA）,glycocholic acid （GCA）,taurocholic acid （TLCA） and total cholic acid （TCA） were assayed by high performance liquid chromatography series mass spectrometry. Results At the end of four-week treatment,the pruritis scores in the observation and control group were（1.1±0.3） vs. （2.3±0.8）,respectively （P<0.05）;serum alanine aminotransferase levels were （25.7±10.0） U/L vs. （85.1 ±24.3） U/L （P<0.05）,serum aspartate aminotransferase levels were （22.6±10.3） U/L vs. （84.3±11.3） U/L （P<0.05） and serum bilirubin levels were （21.6±3.8） μmol/L vs. （30.5±5.4） μmol/L （P<0.05）;serum UDCA levels were （3.2±0.1） μmol/L vs. （2.5±0.2） μmol/L,CA were （1.2±0.1） μmol/L vs. （2.4±0.2） μmol/L,GCA were （1.6±0.2） μmol/L vs. （2.8±0.5） μmol/L and TCA were（1.2±0.3） μmol/L vs.（4.2±0.9） μmol/L,all significantly different（P<0.05）;the incidences of premature delivery,postpartum hemorrhage and neonatal asphyxia in the two groups were significantly different（17.1% vs. 51.4%,P<0.05）. Conclusion The application of UDCA in treatment of patients with ICP has efficacious and safe,which might alleviate the clinical symptoms,and improve liver function tests.

Key words: Intrahepatic cholestasis of pregnancy, Ursodeoxycholic acid, Therapy, Bile acid